Mobile

Prospective, Open-label, Non-comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) with Voriconazole in Patients with Allogeneic Stem Cell Transplants

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000365-35

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of voriconazole as secondary prophylaxis on the rate of occurrence of proven and probable invasive fungal infection (IFI) in allogenic stem cell transplant patients having acute leukemia or acute transformation of chronic myeloid leukemia with previous proven or probable invasive fungal infection from the Day of Transplant until the 12 month Follow-up

Critère d'inclusion

  • Secondary Prophylaxis of Invasive Fungal Infections

Liens